Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of carboplatin plus CPT-11 chemotherapy with accelerated hyperfractionated radiotherapy for elderly patients with limited stage small cell lung cancer (TORG0604).

X
Trial Profile

Phase I/II trial of carboplatin plus CPT-11 chemotherapy with accelerated hyperfractionated radiotherapy for elderly patients with limited stage small cell lung cancer (TORG0604).

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Irinotecan (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Oct 2016 Final analysis results assessing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
    • 26 Sep 2015 Status changed from recruiting to completed, as per University Hospital Medical Information Network - Japan record.
    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top